Login to Your Account



More Amgen M&A; Buying Alantos In $300M Cash Deal

By Jennifer Boggs


Thursday, June 7, 2007
Less than two days after Amgen Inc. said it was picking up a Phase II-stage drug for chronic kidney disease through the acquisition of Ilypsa Inc., the biotech giant announced plans to swallow another small biotech, Alantos Pharmaceuticals Inc., for $300 million cash. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription